Man Group plc Invests $3.53 Million in Alignment Healthcare, Inc. $ALHC

Man Group plc acquired a new stake in Alignment Healthcare, Inc. (NASDAQ:ALHC) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 148,159 shares of the company’s stock, valued at approximately $3,528,000. Man Group plc owned about 0.07% of Alignment Healthcare at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in ALHC. Bank of America Corp DE grew its position in shares of Alignment Healthcare by 156.5% in the first quarter. Bank of America Corp DE now owns 3,215,667 shares of the company’s stock valued at $56,660,000 after purchasing an additional 1,961,778 shares during the last quarter. 1492 Capital Management LLC raised its position in shares of Alignment Healthcare by 61.8% during the 4th quarter. 1492 Capital Management LLC now owns 324,865 shares of the company’s stock worth $6,416,000 after purchasing an additional 124,143 shares during the last quarter. William Blair Investment Management LLC raised its position in shares of Alignment Healthcare by 8.7% during the 4th quarter. William Blair Investment Management LLC now owns 2,305,255 shares of the company’s stock worth $45,529,000 after purchasing an additional 185,303 shares during the last quarter. Simplify Asset Management Inc. lifted its stake in Alignment Healthcare by 92.0% in the 4th quarter. Simplify Asset Management Inc. now owns 262,880 shares of the company’s stock valued at $5,192,000 after buying an additional 125,946 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Alignment Healthcare by 36.5% in the 1st quarter. Principal Financial Group Inc. now owns 544,274 shares of the company’s stock valued at $9,590,000 after buying an additional 145,491 shares in the last quarter. 86.19% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Alignment Healthcare

In related news, CEO John E. Kao sold 298,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $13.88, for a total transaction of $4,136,240.00. Following the completion of the transaction, the chief executive officer owned 790,766 shares of the company’s stock, valued at approximately $10,975,832.08. This represents a 27.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock in a transaction on Monday, June 15th. The shares were sold at an average price of $19.55, for a total transaction of $586,500.00. Following the completion of the transaction, the president owned 947,313 shares in the company, valued at approximately $18,519,969.15. This trade represents a 3.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,009,951 shares of company stock valued at $18,597,287 in the last ninety days. 5.20% of the stock is owned by company insiders.

Alignment Healthcare Trading Down 1.6%

Shares of Alignment Healthcare stock opened at $13.40 on Tuesday. Alignment Healthcare, Inc. has a fifty-two week low of $12.70 and a fifty-two week high of $25.12. The business’s fifty day moving average is $17.93 and its two-hundred day moving average is $18.47. The company has a quick ratio of 1.70, a current ratio of 1.70 and a debt-to-equity ratio of 1.22. The firm has a market cap of $2.78 billion, a PE ratio of 70.53 and a beta of 1.10.

Alignment Healthcare (NASDAQ:ALHC) last released its earnings results on Thursday, July 30th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.13 by $0.04. Alignment Healthcare had a return on equity of 20.02% and a net margin of 0.89%.The firm had revenue of $1.34 billion during the quarter, compared to analyst estimates of $1.31 billion. During the same period in the prior year, the firm posted $0.07 earnings per share. The business’s quarterly revenue was up 31.6% compared to the same quarter last year. Analysts anticipate that Alignment Healthcare, Inc. will post 0.17 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. dropped their price target on Alignment Healthcare from $26.00 to $22.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Barclays reduced their price objective on Alignment Healthcare from $19.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 26th. UBS Group reaffirmed a “neutral” rating on shares of Alignment Healthcare in a research note on Wednesday, July 8th. Wall Street Zen cut Alignment Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Alignment Healthcare in a research note on Tuesday, August 4th. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $23.60.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.